Azenta, Inc.
NASDAQ:AZTAMedical - Instruments & Supplies
-$0.03 today
- Market cap
- $2.13B
- Beta
- 1.40
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$3.87
Volume 0.69M
Average 1.16M
AZTA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Azenta, Inc.NASDAQ: AZTA
Research & Development · Q4 FY2026 · quarter ended Sep 2026
Research & development grows, but more slowly than its trailing trend
Q4 FY2026 research & development of $10.44M rose 26.5% year over year, behind the +31.1% change in trailing-twelve-month research & development. Sequentially, it rose 18.0% from the prior quarter. Over 3 fiscal years it compounded at +3.7% a year.
Context
- Research & development amounted to 6.1% of revenue in FY2026, up 1.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +26.5% toward the trailing-twelve-month pace of +31.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 37.92M USD
- Year-over-year change
- +24.8%
- 4-year CAGR
- +8.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 37.92M | +24.8% |
| FY2025 | 2025-09-30 | 30.39M | -3.6% |
| FY2024 | 2024-09-30 | 31.52M | -7.2% |
| FY2023 | 2023-09-30 | 33.96M | +23.3% |
| FY2022 | 2022-09-30 | 27.54M | — |
Research & Development vs competitors
How AZTA compares with its peers on the latest reported figures
- AZTA's LTM Sep 2026 research & development of $37.92M is the 7th highest of the 10 companies compared; the peer median is $261.1M.
- Its year-over-year change of +31.1% is the highest of 10, against a peer median of -1.6%.
- Research & development amounts to 6.1% of revenue for AZTA, versus a peer median of 8.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.67B | +4.2% | +1.5% | 6.5% | |
| LTM Sep 2026 | $1.41B | -0.7% | -1.7% | 3.0% | |
| LTM Jun 2026 | $726M | -5.7% | -1.2% | 8.7% | |
| LTM Jun 2026 | $393.5M | -1.6% | +18.8% | 11.2% | |
| LTM Jun 2026 | $261.1M | -14.3% | +0.0% | 10.1% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| LTM Sep 2026 | $37.92M | +31.1% | +3.7% | 6.1% | |
| LTM Mar 2026 | $20.31M | +4.0% | -0.3% | 8.2% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| LTM Mar 2026 | $8.14M | +5.5% | -20.0% | 8.2% | |
| Peer median (excluding AZTA) | $261.1M | -1.6% | -0.3% | 8.2% | |
Competitors are the stored peer set for AZTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 555.5M | 665.07M | 573.45M | 593.82M | 621.7M |
| Cost of Revenue | 324.88M | 431.82M | 318.83M | 323.54M | 346.74M |
| Gross Profit | 230.62M | 233.26M | 254.62M | 270.28M | 274.96M |
| Gross Margin | 41.5% | 35.1% | 44.4% | 45.5% | 44.2% |
| Research & Development | 27.54M | 33.96M | 31.52M | 30.39M | 37.92M |
| Selling, General & Admin | 227.1M | 281.5M | 253.08M | 251.16M | 257.53M |
| Operating Expenses | 254.64M | 315.45M | 284.6M | 281.55M | 449.66M |
| Depreciation & Amortization | 53.7M | 85.58M | 90.74M | 61.21M | 0 |
| EBITDA | 48.36M | 55.15M | 71.62M | 54.07M | (151.01M) |
| EBITDA Margin | 8.7% | 8.3% | 12.5% | 9.1% | -24.3% |
| Operating Income | (24.02M) | (82.2M) | (29.98M) | (11.27M) | (174.7M) |
| Operating Margin | -4.3% | -12.4% | -5.2% | -1.9% | -28.1% |
| Interest Income | 20.29M | 43.74M | 33.18M | 18.78M | 17.83M |
| Interest Expense | 4.59M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 14.09M | 51.77M | 10.86M | 4.13M | 23.69M |
| Income Before Tax | (9.94M) | (30.43M) | (19.13M) | (7.14M) | (151.01M) |
| Pre-Tax Margin | -1.8% | -4.6% | -3.3% | -1.2% | -24.3% |
| Income Tax Expense | 1.35M | (17.55M) | 5.24M | (31.6M) | 6.86M |
| Net Income | (428.96M) | (14.26M) | (164.9M) | (55.76M) | (166.99M) |
| Net Margin | -77.2% | -2.1% | -28.8% | -9.4% | -26.9% |
| EPS (Basic) | (0.15) | (0.22) | (3.09) | (1.22) | (3.70) |
| EPS (Diluted) | (0.15) | (0.22) | (3.09) | (1.22) | (3.70) |
| Weighted Avg Shares | 74.9M | 66.25M | 53.18M | 45.74M | 45.13M |
| Weighted Avg Shares (Diluted) | 74.9M | 66.25M | 53.18M | 45.9M | 45.13M |
Azenta, Inc.
NASDAQ:AZTA
Intrinsic Alpha fair value
Locked
Current Price
$48.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.